New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust in the UK, published results from their early-stage breast cancer study in Annals of Oncology. In this groundbreaking study, the authors highlight advancements in breast cancer residual disease (MRD) and recurrence detection using NeXT Personal®, an ultra-sensitive personalized test designed to detect small traces of circulating tumor DNA (ctDNA) in the blood of cancer patients and survivors.The findings of this study highlight the potential for using NeXT Personal in guiding management of breast cancer, currently the most common cancer in the U.S., with an estimated 300,000 new cases and approximately 40,000 deaths forecasted for 2024, according to the U.S. National Cancer Institute (NCI). Personalis’ NeXT Personal assay utilizes whole-ge
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors [Yahoo! Finance]Yahoo! Finance
- Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid TumorsBusiness Wire
- Personalis (NASDAQ:PSNL) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PSNL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung CancerBusiness Wire
- Why Analysts See Personalis Story Shifting With Medicare Tailwinds And Biopharma Headwinds [Yahoo! Finance]Yahoo! Finance
PSNL
Earnings
- 11/4/25 - Beat
PSNL
Sec Filings
- 11/28/25 - Form 8-K
- 11/28/25 - Form 424B5
- 11/28/25 - Form 4
- PSNL's page on the SEC website